← ANALYST RATINGS · TIPRANKS
Connect Biopharma Holdings (CNTB): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $6.86, the highest $10.00, the lowest $4.00. The average is +656.9% from the last price of $0.91.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Unknown Analyst | Leerink Partners | $4.00 | Buy | +341.5% | Reiterated | 12.10.26on TipRanks Oct 15 21:01 | +4.1%next day +1.4% | ↗ |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | $7.00 | Buy | +672.6% | Reiterated | 08.10.26on TipRanks 06:25 | −6.4%next day −1.7% · 5 days +3.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1.00 → $0.97−2.6% | Hold | +7.5% | Reiterated | 02.10.26on TipRanks 05:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.00 → $0.99−1.1% | Hold | +9.2% | Reiterated | 02.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1.00 → $0.96−4.1% | Hold | +5.8% | Reiterated | 02.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1.00 → $0.91−9.0% | Sell | +0.4% | Reiterated | 02.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1.00 → $0.99−0.6% | Hold | +9.7% | Reiterated | 02.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $1.00 → $0.97−3.2% | Hold | +6.8% | Reiterated | 02.10.26on TipRanks 05:06 | — | |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $6.00 | Buy | +562.3% | Reiterated | 01.10.26on TipRanks 07:10 | −11.2%next day −6.1% · 5 days −11.4% | ↗ |
| Thomas Flaten★★★★★★★★★★#1650 · hits 47% · avg +8.9% | Lake Street | $9.00 | Buy | +893.4% | Reiterated | 30.09.26on TipRanks 09:10 | +11.1%next day −11.2% · 5 days −16.1% | ↗ |
| Mazahir Alimohamed★★★★★★★★★★#9079 · hits 50% · avg −1.5% | Oppenheimer | $8.00 → $5.00−37.5% | Buy | +451.9% | Assigned | 22.09.26on TipRanks 08:00 | −7.9%next day −11.2% · 5 days −17.2% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $10.00 | Buy | +1,003.8% | Reiterated | 27.08.26on TipRanks 07:10 | −2.8%next day −2.0% · 5 days −15.6% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $7.00 | Buy | +672.6% | Reiterated | 13.08.26on TipRanks 07:10 | +8.3%next day +0.6% · 5 days −8.3% | ↗ |
| Olivia Brayer★★★★★★★★★★#9632 · hits 39% · avg −1.2% | Cantor Fitzgerald | $4.00 | Buy | +341.5% | Initiated | 21.05.26on TipRanks 06:15 | +2.0%next day −0.8% · 5 days +3.7% | ↗ |
| Carl Byrnes★★★★★★★★★★#11765 · hits 37% · avg −4.0% | Northland Securities | $7.50 | Buy | +727.8% | Reiterated | 24.04.26on TipRanks 09:07 | −0.8%next day −3.0% · 5 days −2.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Connect Biopharma Holdings
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $6.86 at a price of $1.10 (+523.4%); now: $6.86 at $0.91 (+656.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 15 | 13 | 13 | 14 | 17 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.26 (from $-0.32 to $-0.19). Last quarter: $-0.27.
Sales
Next quarter’s sales estimate — $1M (from $0M to $5M). Last quarter: $3M.
Best top-analyst consensus in the sector · Healthcare
About Connect Biopharma Holdings
- CEO: Barry D. Quart
- Employees: 64
- 3580 Carmel Mountain Road, San Diego, CA, 92130, US
- www.connectbiopharma.com
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Data from the stock’s TipRanks forecast page, read 23 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗